Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Hydroxychloroquine for prophylaxis of COVID-19 in health workers: A randomized clinical trial

Rojas-Serrano et al., PLOS ONE, doi:10.1371/journal.pone.0261980 (date from preprint), NCT04318015
May 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Symp. case 82% Improvement Relative Risk HCQ  Rojas-Serrano et al.  Prophylaxis  DB RCT Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Double-blind RCT 127 patients in Mexico (April 2020 - March 2021) Fewer symptomatic cases with HCQ (not stat. sig., p=0.12) c19hcq.org Rojas-Serrano et al., PLOS ONE, May 2021 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19hcq.org
Early terminated HCQ PrEP RCT with 62 HCQ and 65 placebo patients, showing 82% lower cases with treatment, p = 0.12. If the trial is continued and the same event rate is observed, statistical significance will be reached after adding about 16 patients per arm.
risk of symptomatic case, 82.0% lower, RR 0.18, p = 0.12, treatment 1 of 62 (1.6%), control 6 of 65 (9.2%), NNT 13, adjusted per study.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Rojas-Serrano et al., 16 May 2021, Double Blind Randomized Controlled Trial, placebo-controlled, Mexico, peer-reviewed, median age 31.5, 8 authors, study period 14 April, 2020 - 31 March, 2021, trial NCT04318015 (history). Contact: jrojas@iner.gob.mx.
This PaperHCQAll
Hydroxychloroquine For Prophylaxis Of COVID-19 In Health Workers: A Randomized Clinical Trial
Jorge Rojas-Serrano, Angelica Margarita Portillo-Vásquez Thirion-Romero, Joel Vázquez-Pérez, Fidencio Mejía-Nepomuceno Alejandra Ramírez-Venegas, Karla Midori Pérez-Kawabe, Rogelio Pérez-Padilla
doi:10.1101/2021.05.14.21257059
Health care workers are at high risk of being infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). Our aim is to evaluate the efficacy and safety of hydroxychloroquine (HCQ) for prophylaxis of COVID19 in health personnel exposed to patients infected by SARS-COV-2. Methods: Double-blind randomized, placebo-controlled single center clinical trial. Included subjects were health care workers caring for severe COVD19 patients. Main outcome was time to symptomatic SARS-CoV2 infection. Results: 127 subjects with a confirmed baseline negative RT-PCR SARS-CoV2 test were included in the trial, 62 assigned to HCQ and 65 to placebo. One subject (1.6%) in the HCQ group and 6 (9,2%) subjects in the placebo group developed COVID-19. (Log Rank test p = 0.09). No severe COVID19 cases were observed. The study was suspended because of a refusal to participate and losses to follow up after several trials reported lack of effectiveness of hydroxychloroquine in hospitalized patients with COVID-19. CONCLUSION Although the number of symptomatic infections in health personnel was lower in the HCQ group, the difference was not statistically significant. The trial is underpowered due to the failure to complete the estimated sample size.
Hydroxychloroquine For Prophylaxis Of COVID-19 In Health SUMMARY Health care workers are at high risk of being infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). Our aim is to evaluate the efficacy and safety of hydroxychloroquine (HCQ) for prophylaxis of COVID19 in health personnel exposed to infected by SARS-COV-2. Methods: Double-blind randomized, placebo-controlled single center clinical trial. Included subjects were health care workers caring for severe COVD19 patients. Main outcome was time to symptomatic SARS-CoV2 infection. Results: 127 subjects with a confirmed baseline negative RT-PCR SARS-CoV2 test were included in the trial, 62 assigned to HCQ and 65 to placebo. One subject (1.6%) in the HCQ group and 6 (9,2%) subjects in the placebo group developed COVID-19. (Log Rank test p = 0.09). No severe COVID19 cases were observed. The study was suspended because of a refusal to participate and losses to follow up after several trials reported lack of effectiveness of hydroxychloroquine in hospitalized patients with COVID-19. CONCLUSION Although the number of symptomatic infections in health personnel was lower in the HCQ group, the difference was not statistically significant. The trial is underpowered due to the failure to complete the estimated sample size. Key words: COVID-19, health workers, prophylaxis, hydroxychloroquine,
References
Agren, Understanding Mexican Health Worker COVID-19 Deaths, doi:10.1016/S0140-6736(20)31955-3
Bandyopadhyay, Baticulon, Kadhum, Infection and mortality of healthcare workers worldwide from COVID-19: a systematic review, BMJ Glob Heal, doi:10.1136/bmjgh-2020-003097
Barranco, Ventura, Covid-19 and infection in health-care workers: An emerging problem, Med Leg J, doi:10.1177/0025817220923694
Booth, Bruno, Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis, Published, doi:10.1371/journal.pone.0247461
Colaneri, Novelli, Cutti, The experience of the health care workers of a severely hit SARS-CoV-2 referral Hospital in Italy: incidence, clinical course and modifiable risk factors for COVID-19 infection, J Public Health, doi:10.1093/pubmed/fdaa195
Doyno, Sobieraj, Baker, Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose, Clin Toxicol, doi:10.1080/15563650.2020.1817479
Dy, Rabajante, A COVID-19 infection risk model for frontline health care workers, Netw Model Anal Heal Informatics Bioinforma, doi:10.1007/s13721-020-00258-3
Furst, Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases, Lupus
Gies, Bekaddour, Dieudonné, Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine, Front Immunol, doi:10.3389/fimmu.2020.01409
Gohar, Larivière, Nowrouzi-Kia, Sickness absence in healthcare workers during the COVID-19 pandemic, Occup Med (Chic Ill), doi:10.1093/occmed/kqaa093
Horby, Mafham, Linsell, Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2022926
Id, Chaudhuri, Id, The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials, Published, doi:10.1371/journal.pone.0244778
Indre, Para, Para, EL DIAGNÓSTICO DE SARS-CoV-2 DURANTE LA CONTINGENCIA DE COVID-19 EN MÉXICO, doi:10.2807/1560
Mehra, Desai, Ruschitzka, Patel, RETRACTED:Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, Lancet. Published online, doi:10.1016/S0140-6736(20)31180-6
Mehta, Bhandari, Mehta, Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?, J Glob Antimicrob Resist, doi:10.1016/j.jgar.2020.07.022
Nicol, Joshi, Rizk, Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection, Clin Pharmacol Ther. Published online, doi:10.1002/cpt.1993
Oliver, Gargano, Marin, The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine -United States, December 2020, MMWR Morb Mortal Wkly Rep, doi:10.15585/mmwr.mm6950e2
Peder, Id, Wiberg, A systematic review of trial registry entries for randomized clinical trials investigating COVID-19 medical prevention and treatment, Published, doi:10.1371/journal.pone.0237903
Rosenberg, Dufort, Udo, Association of Treatment with Hydroxychloroquine or Azithromycin with In-Hospital Mortality in Patients with COVID-19 in New York State, JAMA -J Am Med Assoc, doi:10.1001/jama.2020.8630
Schulz, Altman, Moher, Consort, Statement: Updated guidelines for reporting parallel group randomised trials, BMJ, doi:10.1136/bmj.c332
Singh, Ryan, Kredo, Chaplin, Fletcher, Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19, Cochrane Database Syst Rev. Published online, doi:10.1002/14651858.cd013587.pub2
Wang, Zhou, Liu, Reasons for healthcare workers becoming infected with novel coronavirus disease 2019 (COVID-19) in China, J Hosp Infect, doi:10.1016/j.jhin.2020.03.002
Wei J Te, Liu, Fan, Zhao, Cao, Epidemiology of and risk factors for COVID-19 infection among health care workers: A multi-centre comparative study, Int J Environ Res Public Health, doi:10.3390/ijerph17197149
White, Watson, Hoglund, Chan, Cheah et al., COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology, PLoS Med, doi:10.1371/journal.pmed.1003252
{ 'indexed': {'date-parts': [[2023, 8, 5]], 'date-time': '2023-08-05T15:29:20Z', 'timestamp': 1691249360390}, 'reference-count': 33, 'publisher': 'Public Library of Science (PLoS)', 'issue': '2', 'license': [ { 'start': { 'date-parts': [[2022, 2, 9]], 'date-time': '2022-02-09T00:00:00Z', 'timestamp': 1644364800000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by/4.0/'}], 'funder': [ {'DOI': '10.13039/100004339', 'name': 'Sanofi', 'doi-asserted-by': 'publisher'}, {'name': 'CONACYT', 'award': ['FORDECYT/07SE/2020/03/31-04']}], 'content-domain': {'domain': ['www.plosone.org'], 'crossmark-restriction': False}, 'abstract': '<jats:sec id="sec001">\n' '<jats:title>Introduction</jats:title>\n' '<jats:p>Health care workers are at high risk of being infected with the severe acute ' 'respiratory syndrome coronavirus 2 (SARS-CoV-2). Our aim is to evaluate the efficacy and ' 'safety of hydroxychloroquine (HCQ) for prophylaxis of coronavirus disease 19 (COVID-19) in ' 'health personnel exposed to patients infected by SARS-CoV-2.</jats:p>\n' '</jats:sec>\n' '<jats:sec id="sec002">\n' '<jats:title>Methods</jats:title>\n' '<jats:p>Double-blind randomized, placebo-controlled single center clinical trial. Included ' 'subjects were health care workers caring for severe COVID-19 patients. Main outcome was time ' 'to symptomatic SARS-CoV-2 infection.</jats:p>\n' '</jats:sec>\n' '<jats:sec id="sec003">\n' '<jats:title>Results</jats:title>\n' '<jats:p>127 subjects with a confirmed baseline negative RT-PCR SARS-CoV2 test were included ' 'in the trial. 62 assigned to HCQ and 65 to placebo. One subject (1.6%) in the HCQ group and 6 ' '(9.2%) subjects in the placebo group developed COVID-19 (Log-Rank test p = 0.07). No severe ' 'COVID-19 cases were observed. The study was suspended because of a refusal to participate and ' 'losses to follow up after several trials reported lack of effectiveness of hydroxychloroquine ' 'in hospitalized patients with COVID-19.</jats:p>\n' '</jats:sec>\n' '<jats:sec id="sec004">\n' '<jats:title>Conclusion</jats:title>\n' '<jats:p>The effect size of hydroxychloroquine was higher than placebo for COVID-19 ' 'symptomatic infection in health personnel, although this was not statistically significant. ' 'The trial is underpowered due to the failure to complete the estimated sample size.</jats:p>\n' '</jats:sec>', 'DOI': '10.1371/journal.pone.0261980', 'type': 'journal-article', 'created': {'date-parts': [[2022, 2, 9]], 'date-time': '2022-02-09T18:27:53Z', 'timestamp': 1644431273000}, 'page': 'e0261980', 'update-policy': 'http://dx.doi.org/10.1371/journal.pone.corrections_policy', 'source': 'Crossref', 'is-referenced-by-count': 11, 'title': 'Hydroxychloroquine for prophylaxis of COVID-19 in health workers: A randomized clinical trial', 'prefix': '10.1371', 'volume': '17', 'author': [ {'given': 'Jorge', 'family': 'Rojas-Serrano', 'sequence': 'first', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-5032-4076', 'authenticated-orcid': True, 'given': 'Angelica Margarita', 'family': 'Portillo-Vásquez', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ireri', 'family': 'Thirion-Romero', 'sequence': 'additional', 'affiliation': []}, {'given': 'Joel', 'family': 'Vázquez-Pérez', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Fidencio', 'family': 'Mejía-Nepomuceno', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Alejandra', 'family': 'Ramírez-Venegas', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Karla Midori', 'family': 'Pérez-Kawabe', 'sequence': 'additional', 'affiliation': []}, {'given': 'Rogelio', 'family': 'Pérez-Padilla', 'sequence': 'additional', 'affiliation': []}], 'member': '340', 'published-online': {'date-parts': [[2022, 2, 9]]}, 'reference': [ { 'issue': '2', 'key': 'pone.0261980.ref001', 'doi-asserted-by': 'crossref', 'first-page': '65', 'DOI': '10.1177/0025817220923694', 'article-title': 'Covid-19 and infection in health-care workers: An emerging problem', 'volume': '88', 'author': 'R Barranco', 'year': '2020', 'journal-title': 'Med Leg J'}, { 'issue': '19', 'key': 'pone.0261980.ref002', 'first-page': '1', 'article-title': 'Epidemiology of and risk factors for COVID-19 infection among health ' 'care workers: A multi-centre comparative study', 'volume': '17', 'author': 'J Te Wei', 'year': '2020', 'journal-title': 'Int J Environ Res Public Health'}, { 'key': 'pone.0261980.ref003', 'first-page': '1', 'article-title': 'The experience of the health care workers of a severely hit SARS-CoV-2 ' 'referral Hospital in Italy: incidence, clinical course and modifiable ' 'risk factors for COVID-19 infection', 'author': 'M Colaneri', 'year': '2020', 'journal-title': 'J Public Health (Bangkok)'}, { 'key': 'pone.0261980.ref004', 'unstructured': 'COVID-19 has infected some 570,000 health workers and killed 2,500 in ' 'the Americas, PAHO Director says—PAHO/WHO | Pan American Health ' 'Organization. Accessed March 7, 2021. ' 'https://www.paho.org/en/news/2-9-2020-covid-19-has-infected-some-570000-health-workers-and-killed-2500-americas-paho'}, { 'key': 'pone.0261980.ref005', 'doi-asserted-by': 'crossref', 'volume-title': 'Understanding Mexican Health Worker COVID-19 Deaths.', 'author': 'D. Agren', 'year': '2020', 'DOI': '10.1016/S0140-6736(20)31955-3'}, { 'issue': '1', 'key': 'pone.0261980.ref006', 'article-title': 'A COVID-19 infection risk model for frontline health care workers', 'volume': '9', 'author': 'LF Dy', 'year': '2020', 'journal-title': 'Netw Model Anal Heal Informatics Bioinforma'}, { 'key': 'pone.0261980.ref007', 'unstructured': 'The Association between the Perceived Adequacy of Workplace Infection ' 'Control Procedures and Personal Protective Equipment with Mental Health ' 'Symptoms: A Cross-sectional Survey of Canadian Health-care Workers ' 'during the COVID-19 Pandemic.'}, { 'issue': '5', 'key': 'pone.0261980.ref008', 'doi-asserted-by': 'crossref', 'first-page': '338', 'DOI': '10.1093/occmed/kqaa093', 'article-title': 'Sickness absence in healthcare workers during the COVID-19 pandemic', 'volume': '70', 'author': 'B Gohar', 'year': '2020', 'journal-title': 'Occup Med (Chic Ill)'}, { 'issue': '1', 'key': 'pone.0261980.ref009', 'doi-asserted-by': 'crossref', 'first-page': '100', 'DOI': '10.1016/j.jhin.2020.03.002', 'article-title': 'Reasons for healthcare workers becoming infected with novel coronavirus ' 'disease 2019 (COVID-19) in China', 'volume': '105', 'author': 'J Wang', 'year': '2020', 'journal-title': 'J Hosp Infect'}, { 'issue': '50', 'key': 'pone.0261980.ref010', 'doi-asserted-by': 'crossref', 'first-page': '1922', 'DOI': '10.15585/mmwr.mm6950e2', 'article-title': 'The Advisory Committee on Immunization Practices’ Interim ' 'Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine—United ' 'States, December 2020', 'volume': '69', 'author': 'SE Oliver', 'year': '2020', 'journal-title': 'MMWR Morb Mortal Wkly Rep'}, { 'issue': '9', 'key': 'pone.0261980.ref011', 'doi-asserted-by': 'crossref', 'first-page': '1', 'DOI': '10.1371/journal.pmed.1003252', 'article-title': 'COVID-19 prevention and treatment: A critical analysis of chloroquine ' 'and hydroxychloroquine clinical pharmacology', 'volume': '17', 'author': 'NJ White', 'year': '2020', 'journal-title': 'PLoS Med'}, { 'key': 'pone.0261980.ref012', 'article-title': 'Pharmacokinetics and Pharmacological Properties of Chloroquine and ' 'Hydroxychloroquine in the Context of COVID-19 Infection', 'author': 'MR Nicol', 'year': '2020', 'journal-title': 'Clin Pharmacol Ther'}, { 'issue': 'July', 'key': 'pone.0261980.ref013', 'first-page': '1', 'article-title': 'Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine', 'volume': '11', 'author': 'V Gies', 'year': '2020', 'journal-title': 'Front Immunol'}, { 'key': 'pone.0261980.ref014', 'doi-asserted-by': 'crossref', 'first-page': '864', 'DOI': '10.1016/j.jgar.2020.07.022', 'article-title': 'Why is pre-exposure prophylaxis with hydroxychloroquine a safe and ' 'rationale approach against SARS-CoV-2 infection?', 'volume': '22', 'author': 'S Mehta', 'year': '2020', 'journal-title': 'J Glob Antimicrob Resist'}, { 'issue': '7748', 'key': 'pone.0261980.ref015', 'first-page': '698', 'article-title': 'CONSORT 2010 Statement: Updated guidelines for reporting parallel group ' 'randomised trials', 'volume': '340', 'author': 'KF Schulz', 'year': '2010', 'journal-title': 'BMJ'}, { 'key': 'pone.0261980.ref016', 'first-page': '499', 'volume-title': 'Rheumatology', 'author': 'VP Bykerk', 'year': '2019', 'edition': '7'}, { 'key': 'pone.0261980.ref017', 'unstructured': 'InDRE. CRITERIOS PARA LA ACEPTACIÓN DE PRUEBAS MOLECULARES ÚTILES PARA ' 'EL DIAGNÓSTICO DE SARS-CoV-2 DURANTE LA CONTINGENCIA DE COVID-19 EN ' 'MÉXICO. Published online 2020:1.'}, { 'key': 'pone.0261980.ref018', 'first-page': '229', 'volume-title': 'Primer of Biostatistics', 'author': 'SA Glantz', 'year': '2012', 'edition': '7'}, { 'key': 'pone.0261980.ref019', 'article-title': 'RETRACTED:Hydroxychloroquine or chloroquine with or without a macrolide ' 'for treatment of COVID-19: a multinational registry analysis', 'author': 'MR Mehra', 'year': '2020', 'journal-title': 'Lancet. Published online'}, { 'issue': '24', 'key': 'pone.0261980.ref020', 'doi-asserted-by': 'crossref', 'first-page': '2493', 'DOI': '10.1001/jama.2020.8630', 'article-title': 'Association of Treatment with Hydroxychloroquine or Azithromycin with ' 'In-Hospital Mortality in Patients with COVID-19 in New York State', 'volume': '323', 'author': 'ES Rosenberg', 'year': '2020', 'journal-title': 'JAMA—J Am Med Assoc'}, { 'key': 'pone.0261980.ref021', 'doi-asserted-by': 'crossref', 'first-page': '2030', 'DOI': '10.1056/NEJMoa2022926', 'article-title': 'Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19', 'volume': '383', 'author': 'P Horby', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': 'pone.0261980.ref022', 'author': 'A Peder', 'year': '2020', 'journal-title': 'A systematic review of trial registry entries for randomized clinical ' 'trials investigating COVID-19 medical prevention and treatment'}, { 'key': 'pone.0261980.ref023', 'article-title': 'Chloroquine or hydroxychloroquine for prevention and treatment of ' 'COVID-19', 'author': 'B Singh', 'year': '2021', 'journal-title': 'Cochrane Database Syst Rev'}, { 'key': 'pone.0261980.ref024', 'author': 'KL Id', 'year': '2021', 'journal-title': 'The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: ' 'A systematic review and meta-analysis of randomized trials'}, { 'issue': '11', 'key': 'pone.0261980.ref025', 'doi-asserted-by': 'crossref', 'first-page': 'E835', 'DOI': '10.1093/cid/ciaa1571', 'article-title': 'Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease ' '2019 (COVID-19) in Healthcare Workers: A Randomized Trial', 'volume': '72', 'author': 'R Rajasingham', 'year': '2021', 'journal-title': 'Clin Infect Dis'}, { 'issue': '2', 'key': 'pone.0261980.ref026', 'doi-asserted-by': 'crossref', 'first-page': '1', 'DOI': '10.1001/jamainternmed.2020.6319', 'article-title': 'Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure ' 'SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical ' 'Trial', 'volume': '181', 'author': 'BS Abella', 'year': '2021', 'journal-title': 'JAMA Intern Med'}, { 'issue': 'Suppl 1', 'key': 'pone.0261980.ref027', 'doi-asserted-by': 'crossref', 'first-page': 'S11', 'DOI': '10.1177/0961203396005001041', 'article-title': 'Pharmacokinetics of hydroxychloroquine and chloroquine during treatment ' 'of rheumatic diseases', 'volume': '5', 'author': 'DE Furst', 'year': '1996', 'journal-title': 'Lupus'}, { 'key': 'pone.0261980.ref028', 'first-page': '3097', 'article-title': 'Infection and mortality of healthcare workers worldwide from COVID-19: ' 'a systematic review', 'volume': '5', 'author': 'S Bandyopadhyay', 'year': '2020', 'journal-title': 'BMJ Glob Heal'}, { 'key': 'pone.0261980.ref029', 'unstructured': 'DOF—Diario Oficial de la Federación. Accessed March 21, 2021. ' 'https://www.dof.gob.mx/nota_detalle.php?codigo=5597618&fecha=31/07/2020'}, { 'key': 'pone.0261980.ref030', 'author': 'A Booth', 'year': '2021', 'journal-title': 'Population risk factors for severe disease and mortality in COVID-19: A ' 'global systematic review and meta-analysis'}, { 'issue': '1', 'key': 'pone.0261980.ref031', 'doi-asserted-by': 'crossref', 'DOI': '10.1080/15563650.2020.1817479', 'article-title': 'Toxicity of chloroquine and hydroxychloroquine following therapeutic ' 'use or overdose', 'volume': '59', 'author': 'C Doyno', 'year': '2020', 'journal-title': 'Clin Toxicol'}, { 'key': 'pone.0261980.ref032', 'unstructured': 'Another study finds hydroxychloroquine does not help Covid-19 ' 'patients—CNN. Accessed March 21, 2021. ' 'https://edition.cnn.com/2020/07/23/health/hydroxychloroquine-covid-brazil-study/index.html'}, { 'key': 'pone.0261980.ref033', 'unstructured': '¿Por qué suspendió la OMS los ensayos de la hidroxicloroquina?—AS ' 'México. Accessed March 21, 2021. ' 'https://mexico.as.com/mexico/2020/07/05/actualidad/1593966758_533405.html'}], 'container-title': 'PLOS ONE', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://dx.plos.org/10.1371/journal.pone.0261980', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 2, 9]], 'date-time': '2022-02-09T18:28:33Z', 'timestamp': 1644431313000}, 'score': 1, 'resource': {'primary': {'URL': 'https://dx.plos.org/10.1371/journal.pone.0261980'}}, 'subtitle': [], 'editor': [{'given': 'Elizabeth W', 'family': 'Triche', 'sequence': 'first', 'affiliation': []}], 'short-title': [], 'issued': {'date-parts': [[2022, 2, 9]]}, 'references-count': 33, 'journal-issue': {'issue': '2', 'published-online': {'date-parts': [[2022, 2, 9]]}}, 'URL': 'http://dx.doi.org/10.1371/journal.pone.0261980', 'relation': {}, 'ISSN': ['1932-6203'], 'subject': ['Multidisciplinary'], 'container-title-short': 'PLoS ONE', 'published': {'date-parts': [[2022, 2, 9]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit